Pilot Randomized Trial of a Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer.

J Pain Symptom ManageMay 30, 2026 (epub)
Clinical ResearchOncology (Medical)GastroenterologyOpen access

Kelsey S Lau-Min, Riley Psenka, Mia Holtze et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the feasibility and acceptability of the PATHWAYS supportive care intervention for patients starting multimodality therapy for locally advanced rectal cancer (LARC). Among 20 enrolled patients, 90% of those receiving PATHWAYS completed the intervention, with 100% reporting it as acceptable. The study highlights the potential for tailored support in this patient population.

Key findings

  • 59% of eligible patients enrolled in the study.
  • 90% of PATHWAYS participants completed the intervention.
  • 100% of PATHWAYS participants found the intervention acceptable.

Why it matters

The complexity of multimodality therapy for LARC can overwhelm patients. Effective supportive care interventions like PATHWAYS may enhance patient engagement and satisfaction, potentially improving overall treatment experiences.

Source

Published in J Pain Symptom Manage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.